Scilex Holding (SCLX) Total Non-Current Liabilities (2020 - 2026)

Scilex Holding (SCLX) posted quarterly Total Non-Current Liabilities of $522.2 million for Q1 2026, up 121.57% year-over-year from $235.7 million in Q1 2025, and down 9.43% on a QoQ basis from $576.6 million in Q4 2025.

Scilex Holding (SCLX) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Scilex Holding (SCLX) has reported Total Non-Current Liabilities for 7 consecutive years, with $522.2 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities rose 121.57% year-over-year to $522.2 million; the TTM figure through Mar 2026 stood at $522.2 million (up 121.57% YoY), while the FY2025 annual figure was $576.6 million, up 102.59% from the prior year.
  • Total Non-Current Liabilities came in at $522.2 million for Q1 2026 at Scilex Holding, down from $576.6 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $576.6 million in Q4 2025, with the low at $11.0 million in Q3 2022.
  • Average Total Non-Current Liabilities over 5 years is $237.2 million, with a median of $272.7 million recorded in 2023.
  • Across the five-year window, Total Non-Current Liabilities slumped 81.57% in 2022 and jumped 2090.64% in 2023, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $49.1 million in 2022, then jumped by 455.94% to $272.7 million in 2023, then advanced by 4.35% to $284.6 million in 2024, then soared by 102.59% to $576.6 million in 2025, then retreated by 9.43% to $522.2 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $522.2 million, $576.6 million, and $373.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 48.74 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 119.22 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 109.01 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -34.06 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 75.17 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 31.56 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 113.51 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - 100.00 Mn
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn 522.16 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 522.16 Mn
Dec 31, 2025 576.56 Mn
Sep 30, 2025 373.62 Mn
Jun 30, 2025 332.58 Mn
Mar 31, 2025 235.67 Mn
Dec 31, 2024 284.59 Mn
Sep 30, 2024 300.29 Mn
Jun 30, 2024 319.05 Mn
Mar 31, 2024 274.09 Mn
Dec 31, 2023 272.73 Mn
Sep 30, 2023 241.10 Mn
Jun 30, 2023 109.48 Mn
Mar 31, 2023 68.49 Mn
Dec 31, 2022 49.06 Mn
Sep 30, 2022 11.01 Mn
Jun 30, 2022 51.65 Mn
Mar 31, 2022 11.02 Mn
Dec 31, 2021 266.11 Mn
Sep 30, 2021 5.23 Mn
Jun 30, 2021 5.21 Mn